


IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Original): A sulfonamide compound of general formula (Ia)



(Ia)

wherein

$R^1$  represents an  $-NR^8R^9$  radical or a saturated or unsaturated, optionally at least mono-substituted, cycloaliphatic radical, which may optionally contain at least one heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring system, which may optionally contain at least one heteroatom as a ring member,

$R^2$ ,  $R^3$ ,  $R^4$ ,  $R^6$  and  $R^7$ , identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical or an optionally at least mono-substituted phenyl radical or an optionally at least mono-substituted heteroaryl radical,

$R^5$  represents hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

$R^8$  and  $R^9$ , identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

with the proviso that  $R^8$  and  $R^9$  are not hydrogen at the same time, and if one of them,  $R^8$  and  $R^9$ , represents a saturated or unsaturated, linear or branched, optionally at least mono-substituted  $C_1$ - $C_4$  aliphatic radical, the other one represents a saturated or unsaturated, linear or

branched, optionally at least mono-substituted aliphatic radical with at least five carbon atoms,

or

$R^8$  and  $R^9$  together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted heterocyclic ring, which may contain at least one additional heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, mono- or bicyclic cycloaliphatic ring system which may optionally contain at least one heteroatom as a ring member,

$A$  represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings,






and

$n$  is 0, 1, 2, 3 or 4;

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding, physiologically acceptable salt thereof, or a corresponding solvate thereof.

Claim 2 (Original): A compound according to claim 1, characterized in that  $R^1$  represents an  $-NR^8R^9$  radical or a saturated or unsaturated, optionally at least mono-substituted 5- or 6-membered cycloaliphatic radical which may optionally contain at least one heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring system, which may optionally contain at least one heteroatom as a ring member, whereby the rings of the ring system are 5- or 6-membered,

preferably  $R^1$  represents an  $-NR^8R^9$  radical or a radical chosen from the group consisting of



wherein, if present, the dotted line is an optional chemical bond, and  $R^{10}$  represents hydrogen, a linear or branched  $C_1$ - $C_6$  alkyl radical or a benzyl radical, preferably hydrogen or a  $C_1$ - $C_2$  alkyl radical.

**Claim 3 (Currently Amended):** A compound according to claim 1 [[or 2]], characterized in that  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^6$  and  $R^7$ , identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted  $C_1$ - $C_6$  alkyl radical, a linear or branched, optionally at least mono-substituted  $C_2$ - $C_6$  alkenyl radical or a linear or branched, optionally at least mono-substituted  $C_2$ - $C_6$  alkynyl radical,

preferably  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^6$  and  $R^7$ , identical or different, each represent hydrogen or a linear or branched, optionally at least mono-substituted  $C_1$ - $C_6$  alkyl radical, more preferably  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^6$  and  $R^7$  each represent hydrogen or  $C_{1-2}$  alkyl.

**Claim 4 (Currently Amended):** A compound according to one or more of claims 1 [[to 3]], characterized in that  $R^5$  represents hydrogen, a linear or branched, optionally at least mono-substituted  $C_1$ - $C_6$  alkyl radical, a linear or branched, optionally at least mono-substituted  $C_2$ - $C_6$  alkenyl radical, a linear or branched, optionally at least mono-substituted  $C_2$ - $C_6$  alkynyl radical,

preferably R<sup>5</sup> represents hydrogen or a linear or branched, optionally at least mono-substituted C<sub>1</sub>-C<sub>6</sub> alkyl radical,


more preferably R<sup>5</sup> represents hydrogen or a C<sub>1</sub>-C<sub>2</sub> alkyl radical.

Claim 5 (Currently Amended): A compound according to ~~one or more of claims~~ claim 1 [[to 4]], characterized in that R<sup>8</sup> and R<sup>9</sup>, identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C<sub>1</sub>-C<sub>10</sub> alkyl radical, a linear or branched, optionally at least mono-substituted C<sub>2</sub>-C<sub>10</sub> alkenyl radical, a linear or branched, optionally at least mono-substituted C<sub>2</sub>-C<sub>10</sub> alkynyl radical,

or

R<sup>8</sup> and R<sup>9</sup> together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted 5- or 6-membered heterocyclic ring which may contain at least one additional heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring system, which may optionally contain at least one heteroatom as a ring member, whereby the rings of the ring system are 5-6- or 7-membered.

Claim 6 (Original): A compound according to claim 5, characterized in that R<sup>8</sup> and R<sup>9</sup>, identical or different, each represent hydrogen or a linear or branched C<sub>1</sub>-C<sub>10</sub> alkyl radical, or R<sup>8</sup> and R<sup>9</sup> together with the bridging nitrogen atom form a radical chosen from the group consisting of




wherein  $\text{R}^{11}$ , if present, represents hydrogen, a linear or branched  $\text{C}_1\text{-C}_6$  alkyl radical or a benzyl radical, preferably hydrogen, or a  $\text{C}_1\text{-C}_2$  alkyl radical.

Claim 7 (Currently Amended): A compound according to ~~claim 1 one or more of claims 1 to 6~~, characterized in that A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered, which may be bonded via an optionally at least mono-substituted  $\text{C}_1\text{-C}_6$  alkylene group, an optionally at least mono-substituted  $\text{C}_2\text{-C}_6$  alkenylene group or an optionally at least mono-substituted  $\text{C}_2\text{-C}_6$  alkynylene group and/or wherein the ring(s) may contain at least one heteroatom as a ring member,

preferably A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered and wherein one or more of the rings contain at least one heteroatom,

or a radical chosen from the group consisting of



wherein X, Y, Z, independently from one another, each represent a radical selected from the group consisting of hydrogen, fluorine, chlorine, bromine, nitro, acetyl, linear or branched C<sub>1</sub>-C<sub>6</sub> alkyl, linear or branched C<sub>1</sub>-C<sub>6</sub> alkoxy, linear or branched C<sub>1</sub>-C<sub>6</sub> alkylthio, a trifluoromethyl radical, a cyano radical and a -NR<sup>12</sup>R<sup>13</sup> radical,

wherein R<sup>12</sup> and R<sup>13</sup>, identical or different, each represent hydrogen or linear or branched C<sub>1</sub>-C<sub>6</sub> alkyl,

W represents a single chemical bond between the two rings, a CH<sub>2</sub>, O, S group or a NR<sup>14</sup> radical,

wherein R<sup>14</sup> is hydrogen or a linear or branched C<sub>1</sub>-C<sub>6</sub> alkyl,

m is 0, 1, 2, 3 or 4 and

m1 is 1 or 2.


Claim 8 (Currently Amended): A compound according to ~~one or more of claims 1 to 7~~ chosen from the group consisting of

[16] N-[1-(2-pyrrolidine-1-yl-ethyl)-1H-indole-5-yl]-naphthalene-2-sulfonamide,

- [17] N-[1-(2-pyrrolidine-1-yl-ethyl)-1H-indole-5-yl]-naphthalene-1-sulfonamide,
- [18] N-[1-(2-pyrrolidine-1-yl-ethyl)-1H-indole-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulfonamide,
- [28] N-[1-(2-pyrrolidine-1-yl-ethyl)-1H-indole-5-yl]- ]-6-chloroimidazo[2,1-b]thiazole-5-sulfonamide,
- [43] 5-chloro-3-methyl-N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)benzo[b]thiophene-2-sulfonamide,
- [44] N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)naphthalene-2-sulfonamide,
- [45] N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)naphthalene-1-sulfonamide,
- [46] 6-chloro-N-(1-(3-piperidin-1-yl)propyl)-1H-indol-5-yl)imidazo[2, 1-b]thiazole-5-sulfonamide,
- [47] 4-phenyl-N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)benzenesulfonamide,
- [48] 2-(naphth-1-yl)-N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)ethanesulfonamide,
- [49] 4-phenoxy-N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)benzenesulfonamide,
- [50] 3,5-dichloro-N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)benzenesulfonylamine,
- [51] 4,5-dichloro-N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)thiophene-2-sulfonamide and
- [52] 5-chloro-N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)naphthalene-1-sulfonamide,

optionally in form of their corresponding salts or their corresponding solvates.

Claim 9 (Original): A sulfonamide compound of general formula (Ib)



(Ib)

wherein

R<sup>1</sup> represents a -NR<sup>8</sup>R<sup>9</sup> radical,

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>6</sup> and R<sup>7</sup>, identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, optionally at least mono-substituted, linear or branched aliphatic radical, or an optionally at least mono-substituted phenyl or an optionally at least mono-substituted heteroaryl radical,

R<sup>5</sup> represents hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

R<sup>8</sup> and R<sup>9</sup>, identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted, C<sub>1</sub>-C<sub>4</sub> aliphatic radical,

A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings,

and n is 0, 1, 2, 3 or 4;

optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or a salt thereof, preferably a corresponding, physiologically acceptable salt thereof, or a corresponding solvate thereof.

Claim 10 (Original): A compound according to claim 9, characterized in that  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^6$  and  $R^7$ , identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted  $C_1$ - $C_6$  alkyl radical, a linear or branched, optionally at least mono-substituted  $C_2$ - $C_6$  alkenyl radical, or a linear or branched, optionally at least mono-substituted  $C_2$ - $C_6$  alkynyl radical,

preferably  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^6$  and  $R^7$ , identical or different, each represent hydrogen or a linear or branched, optionally at least mono-substituted  $C_1$ - $C_6$  alkyl radical,  
more preferably  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^6$  and  $R^7$  each represent hydrogen or a  $C_{1-2}$  alkyl radical.

Claim 11 (Currently Amended): A compound according to claim 9 [[or 10]], characterized in that  $R^5$  represents hydrogen, a linear or branched, optionally at least mono-substituted  $C_1$ - $C_6$  alkyl radical, a linear or branched, optionally at least mono-substituted  $C_2$ - $C_6$  alkenyl radical or a linear or branched, optionally at least mono-substituted  $C_2$ - $C_6$  alkynyl radical,

preferably  $R^5$  represents hydrogen or a linear or branched, optionally at least mono-substituted  $C_1$ - $C_6$  alkyl radical,  
more preferably  $R^5$  represents hydrogen or a  $C_1$ - $C_2$  alkyl radical.

Claim 12 (Currently Amended): A compound according to claim 9 one or more of claims 9 to 11, characterized in that  $R^8$  and  $R^9$ , identical or different, each represent hydrogen or a linear or branched, optionally at least mono-substituted  $C_1$ - $C_4$  alkyl radical,


preferably  $R^8$  and  $R^9$ , identical or different, each represent hydrogen or a  $C_1$ - $C_2$  alkyl radical,

with the proviso that  $R^8$  and  $R^9$  are not hydrogen at the same time.

Claim 13 (Currently Amended) A compound according to claim 9 one or more of claims 9 to 12, characterized in that A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered, which may be bonded via an optionally at least mono-substituted C<sub>1</sub>-C<sub>6</sub> alkylene group, an optionally at least mono-substituted C<sub>2</sub>-C<sub>6</sub> alkenylene group or an optionally at least mono-substituted C<sub>2</sub>-C<sub>6</sub> alkynylene group and/or wherein the ring(s) may contain at least one heteroatom as a ring member,

preferably A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered and wherein one or more of the rings contain at least one heteroatom,

or a radical chosen from the group consisting of



wherein X, Y, Z, independently from one another, each represent a s radical selected from the group consisting of hydrogen, fluorine, chlorine, bromine, nitro, acetyl, linear or branched C<sub>1</sub>-C<sub>6</sub> alkyl, linear or branched C<sub>1</sub>-C<sub>6</sub> alkoxy, linear or branched C<sub>1</sub>-C<sub>6</sub> alkylthio, a trifluoromethyl radical, a cyano radical and a -NR<sup>12</sup>R<sup>13</sup> radical,

wherein R<sup>12</sup> and R<sup>13</sup>, identical or different, each represent hydrogen or linear or branched C<sub>1</sub>-C<sub>6</sub> alkyl,

W represents a single chemical bond between the two rings, a CH<sub>2</sub>, O, S group or a NR<sup>14</sup> radical,

wherein R<sup>14</sup> is hydrogen or a linear or branched C<sub>1</sub>-C<sub>6</sub> alkyl,

m is 0, 1, 2, 3 or 4 and

m1 is 1 or 2.

Claim 14 (Currently Amended): A compound according to claim 1 one or more of claims 9 to 13 selected from the group consisting of

- [1] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulfonamide,
- [2] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-naphthalene-2-sulfonamide,
- [3] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-naphthalene-1-sulfonamide,
- [4] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-5-chloronaphthalene-1-sulfonamide,
- [5] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-benzenesulfonamide,
- [6] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-quinoline-8-sulfonamide,
- [7] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-4-phenoxybenzenesulfonamide,
- [8] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-4-methylbenzenesulfonamide,
- [9] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-5-chlorothiophene-2-sulfonamide,
- [10] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-benzo[1,2,5]thiadiazole-4-sulfonamide,
- [11] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-6-chloroimidazo[2,1-b]thiazole-5-sulfonamide,
- [12] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-3,5-dichlorobenzenesulfonamide,

- [13] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-3-bromobenzenesulfonamide,
- [14] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-3-nitrobenzenesulfonamide,
- [15] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-1-phenylmethanesulfonamide,
- [19] trans-N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-2-phenylethanesulfonamide,
- [20] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-4,5-dichlorothiophene-2-sulfonamide,
- [21] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-4-acetylbenzenesulfonamide,
- [22] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-4-bromobenzenesulfonamide,
- [23] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-4-methoxybenzenesulfonamide,
- [24] N-[3-(2-diethylaminoethyl)-1H-indole-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulfonamide,
- [25] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-4-nitrobenzenesulfonamide,
- [26] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-4-fluorobenzenesulfonamide,
- [27] N-[1-(2-diethylaminoethyl)-1H-indole-5-yl]-6-chloroimidazo[2,1-b]thiazole-5-sulfonamide,
- [29] N-(1-(2-(diethylamino)ethyl)-1H-indol-5-yl)-naphthalene-2-sulfonamide,
- [30] N-(1-(2-(diethylamino)ethyl)-1H-indol-5-yl)-naphthalene-1-sulfonamide,
- [31] N-(1-(2-(diethylamino)ethyl)-1H-indol-5-yl)-4-phenylbenzenesulfonamide,
- [32] 5-chloro-N-(1-(2-(dimethylamino)ethyl)-2-methyl-1H-indol-5-yl)-3-methylbenzo[b]thiophene-2-sulfonamide,
- [33] N-(1-(2-(dimethylamino)ethyl)-2-methyl-1H-indol-5-yl)-naphthalene-2-sulfonamide,
- [34] N-(1-(2-(dimethylamino)ethyl)-2-methyl-1H-indol-5-yl)-naphthalene-1-sulfonamide,
- [35] 6-chloro-N-(1-(2-(dimethylamino)ethyl)-2-methyl-1H-indol-5-yl)imidazo[2,1-b]thiazole-5-sulfonamide,

[36] N-(1-(2-(dimethylamino)ethyl)-2-methyl-1H-indol-5-yl)-4-phenylbenzenesulfonamide,

[37] N-(1-(2-dimethylamino)ethyl)-2-methyl-1H-indol-5-yl)-2-(naphth-1-yl)-ethanesulfonamide,

[38] N-(1-(2-(dimethylamino)ethyl)-2-methyl-1H-indol-5-yl)-4-phenoxybenzenesulfonamide,


[39] 3,5-dichloro-N-(1-(2-(dimethylamino)ethyl)-2-methyl-1H-indol-5-yl)-benzenesulfonamide,

[40] N-(1-(2-(dimethylamino)ethyl)-2-methyl-1H-indol-5-yl)benzo[b]thiophene-3-sulfonamide,

[41] N-(1-(2-(diethylamino)ethyl)-1H-indol-5-yl)benzo[b]thiophene-3-sulfonamide and


[42] N-(1-(2-(dimethylamino)ethyl)-1H-indol-5-yl)benzo[b]thiophene-3-sulfonamide, optionally in form of their corresponding salts and their corresponding solvates.

Claim 15 (Withdrawn - Currently Amended): A process for obtaining a sulfonamide derivative of general formula (Ia) and/or (Ib), according to claim 1 one or more of claims 1-14, characterized in that at least one compound of general formula (II), or one of its suitably protected derivatives,



(II)

wherein A has the meaning according to one or more of claims 1-14, and X is an acceptable leaving group, preferably an halogen atom, more preferably chlorine is reacted with at least one 5-aminoindole of general formula (III), or one of its suitably protected derivatives;



(III)

wherein R<sup>1</sup>-R<sup>7</sup> and n have the meaning according to one or more of claims 1-14 to obtain the corresponding sulfonamide and optionally, from the latter, the protective groups may be removed if necessary.

Claim 16 (Withdrawn - Currently Amended): A process for obtaining a sulfonamide derivative of general formula (Ia) and/or (Ib) according to claim 1 one or more of claims 1-14,

wherein R<sup>1</sup>-R<sup>4</sup>, R<sup>6</sup>-R<sup>7</sup>, n and A have the meaning according to one or more of claims 1-14, and R<sup>5</sup> represents C<sub>1</sub>-C<sub>6</sub> alkyl, characterized in that

at least one compound of general formula (Ia) and/or at least one compound of general formula (Ib), wherein R<sup>1</sup>-R<sup>4</sup>, R<sup>6</sup>-R<sup>7</sup>, n and A have the meaning according to claim 1 one or more of claims 1-14, and R<sup>5</sup> represents an hydrogen atom, is reacted with an alkyl halogenide or dialkyl sulfate.

Claim 17 (Withdrawn - Currently Amended): A process for preparing the salts, preferably the physiologically acceptable salts of the compounds of general formula (Ia) and/or (Ib), according to claim 1 one or more of claims 1-14, consisting in reacting at least one compound of the general formula (Ia) and/or at least one compound of the general formula (Ib) with a mineral acid or an organic acid in a **suitable** solvent.

Claim 18 (Currently Amended): A medicament comprising at least one compound according to claim 1 ~~one or more of claims 1 to 8~~ and optionally at least one or more of pharmacologically acceptable excipients.

Claim 19 (Original): A medicament according to claim 18, for 5-HT<sub>6</sub> receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome, for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease, Parkinson's disease, Huntington's disease and/or multiple sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit/hyperactivity disorder),

preferably for 5-HT<sub>6</sub> receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome.

Claim 20 (Withdrawn - Currently Amended): The use of at least one A method for regulating the 5-HT<sub>6</sub> receptor in a patient in need of such regulation by administering a

therapeutic amount of a compound according to claim 1 one or more of claims 1 to 8 for the manufacture of a medicament for 5-HT<sub>6</sub> receptor regulation.

Claim 21 (Withdrawn - Currently Amended): The use of at least one A method for treating a disorder or disease related to food intake in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 1 one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of a disorder or disease related to food intake.

Claim 22 (Withdrawn - Currently Amended): The use of at least one A method for regulating appetite in a patient in need of such regulation by administering a therapeutic amount of a compound according to claim 1 one or more of claims 1 to 8 for the manufacture of a medicament for the regulation of appetite.

Claim 23 (Withdrawn - Currently Amended): The use of at least one A method for controlling body weight in a patient in need of such control by administering a therapeutic amount of a compound according to claim 1 one or more of claims 1 to 8 for the manufacture of a medicament for the maintenance, increase or reduction of body weight.

Claim 24 (Withdrawn - Currently Amended): The use of at least one A method for treating obesity in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 1 one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of obesity.

Claim 25 (Withdrawn - Currently Amended): The use of at least one A method for treating bulimia in a patient in need of such treatment by administering a therapeutic amount of a

compound according to claim 1 ~~one or more of claims 1 to 8 for the manufacture of a medicament for prophylaxis and/or treatment of bulimia.~~

Claim 26 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating anorexia in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 1 ~~one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of anorexia.~~~~

Claim 27 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating cachexia in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 1 ~~one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of cachexia.~~~~

Claim 28 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating type II diabetes in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 1 ~~one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity.~~~~

Claim 29 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating a gastrointestinal tract disorder in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 1 ~~one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of gastrointestinal tract disorders.~~~~

Claim 30 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating irritable bowel syndrome in a patient in need of such treatment by administering a compound according to claim 1 one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of irritable bowel syndrome.~~

Claim 31 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating anxiety in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 1 one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of anxiety.~~

Claim 32 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating depression in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 1 one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of depression.~~

Claim 33 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating a bipolar disorder in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 1 one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of bipolar disorders.~~

Claim 34 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating a cognitive memory disorder in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 1 one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of cognitive memory disorders.~~

Claim 35 (Withdrawn - Currently Amended): The use of at least one A method for treating a senile dementia process in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 1 one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of senile dementia processes.

Claim 36 (Withdrawn - Currently Amended): The use of at least one A method for treating Alzheimer's Disease in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 1 one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of Alzheimer's Disease.

Claim 37 (Withdrawn - Currently Amended): The use of at least one A method for treating Parkinson's Disease in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 1 one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of Parkinson's Disease.

Claim 38 (Withdrawn - Currently Amended): The use of at least one A method for treating Huntington's Disease in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 1 one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of Huntington's Disease.

Claim 39 (Withdrawn - Currently Amended): The use of at least one A method for treating dementia in which a cognitive deficit predominates in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 1 one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of dementias in which a cognitive deficit predominates.

Claim 40 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating Multiple Sclerosis in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 1 one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of Multiple Sclerosis.~~

Claim 41 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating psychosis in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 1 one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of psychosis.~~

Claim 42 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating infantile hyperkinesia in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 1 one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of infantile hyperkinesia (ADHD, attention deficit/hyperactivity disorder).~~

Claim 43 (Withdrawn -Currently Amended): ~~The use of at least one A method for treating a disorder of the central nervous system in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 1 one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of the central nervous system.~~

Claim 44 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating schizophrenia in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 1 one or more of claims 1 to 8 for the manufacture of a medicament for the prophylaxis and/or treatment of schizophrenia.~~

Claim 45 (Withdrawn - Currently Amended): ~~The use of at least one A method for enhancing cognition in a patient in need of such enhancement by administering a therapeutic amount of a compound according to claim 1 one or more of claims 1 to 8 for the manufacture of a medicament for cognitive enhancement.~~

Claim 46 (Currently Amended): A medicament comprising at least one compound according to ~~claim 9 one or more of claims 9 to 14~~ and optionally at least one or more of pharmacologically acceptable excipients.

Claim 47 (Original): A medicament according to claim 46 for 5-HT<sub>6</sub> receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome, for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease, Parkinson's disease, Huntington's disease and/or multiple sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit/hyperactivity disorder), preferably for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit/hyperactivity disorder).

Claim 48 (Withdrawn - Currently Amended): ~~The use of at least one A method for regulating the 5-HT<sub>6</sub> receptor in a patient in need of such regulation by administering a therapeutic amount of a compound according to claim 9 one or more of claims 9 to 14 for the manufacture of a medicament for 5-HT<sub>6</sub> receptor regulation.~~

Claim 49 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating a disorder or disease related to food intake in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 9 one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of a disorder or disease related to food intake.~~

Claim 50 (Withdrawn - Currently Amended): ~~The use of at least one A method for regulating appetite in a patient in need of such regulation by administering a therapeutic amount of a compound according to claim 9 one or more of claims 9 to 14 for the manufacture of a medicament for the regulation of appetite.~~

Claim 51 (Withdrawn - Currently Amended): ~~The use of at least one A method for controlling body weight in a patient in need of such control by administering a therapeutic amount of a compound according to claim 9 one or more of claims 9 to 14 for the manufacture of a medicament for the maintenance, increase or reduction of body weight.~~

Claim 52 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating obesity in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 9 one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of obesity.~~

Claim 53 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating bulimia in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 9 one or more of claims 9 to 14 for the manufacture of a medicament for prophylaxis and/or treatment of bulimia.~~

Claim 54 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating anorexia in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 9 one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of anorexia.~~

Claim 55 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating cachexia in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 9 one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of cachexia.~~

Claim 56 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating type II diabetes in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 9 one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity.~~

Claim 57 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating a gastrointestinal tract disorder in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 9 one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of gastrointestinal tract disorders.~~

Claim 58 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating irritable bowel syndrome in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 9 one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of irritable bowel syndrome.~~

Claim 59 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating anxiety in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 9 one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of anxiety.~~

Claim 60 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating depression in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 9 one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of depression.~~

Claim 61 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating a bipolar disorder in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 9 one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of bipolar disorders.~~

Claim 62 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating a cognitive memory disorder in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 9 one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of cognitive memory disorders.~~

Claim 63 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating a senile dementia process in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 9 one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of senile dementia processes.~~

Claim 64 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating Alzheimer's Disease in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 9 one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of Alzheimer's Disease.~~

Claim 65 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating Parkinson's Disease in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 9 one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of Parkinson's Disease.~~

Claim 66 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating Huntington's Disease in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 9 to one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of Huntington's Disease.~~

Claim 67 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating Multiple Sclerosis in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 9 one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of Multiple Sclerosis.~~

Claim 68 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating dementia in which a cognitive deficit predominates in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 9 one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of dementias in which a cognitive deficit predominates.~~

Claim 69 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating psychosis in a patient in need of such treatment by administering v a compound according to claim 9 one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of psychosis.~~

Claim 70 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating infantile hyperkinesia in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 9 one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of infantile hyperkinesia (ADHD, attention deficit/hyperactivity disorder).~~

Claim 71 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating a disorder of the central nervous system in a patient in need of such treatment by administering a therapeutic amount of a compound according to claim 9 one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of the central nervous system.~~

Claim 72 (Withdrawn - Currently Amended): ~~The use of at least one A method for treating schizophrenia in a patient in need of such treatment by administering a therapeutic~~

~~amount of a compound according to claim 9 one or more of claims 9 to 14 for the manufacture of a medicament for the prophylaxis and/or treatment of schizophrenia.~~

Claim 73 (Withdrawn - Currently Amended): ~~The use of at least one A method for enhancing cognition in a patient in need of such enhancement by administering a therapeutic amount of a compound according to claim 9 one or more of claims 9 to 14 for the manufacture of a medicament for cognitive enhancement.~~